Previous 10 | Next 10 |
Looking For The Best Health Care Stocks To Watch Right Now? 4 Names To Know You can’t deny that health care is a vital industry in the world we live in today. Similarly, health care stocks have and will likely continue to fill the same role in the stock market. With all e...
Shares of PRA Health Sciences (NASDAQ: PRAH) , a contract research organization (CRO), are jumping on Wednesday and were up by 18.2% as of 1:27 p.m. EST. There are two reasons investors are bidding up PRA Health Sciences' stock today. First, the company reported better-than-expected...
William Blair analyst John Kreger likes what he sees with ICON plc's (ICLR) $12B acquisition of PRA Health Sciences (PRAH) announced earlier today."We know that ICON has been striving for greater scale in the business and PRA Health should be a very complementary fit in terms of customer...
LabCorp (LH) sum-of-the-parts value is $313 share, 27% higher than its current price, as activist Jana may unlock the value in the company's Covance business, according to Credit Suisse.LabCorp's Covance CRO business is "woefully underappreciate," Credit Suisse analyst Erin Wilson Wright says...
PRA Health Sciences (PRAH) has surged ~19.0% in the premarket after agreeing to be acquired by ICON plc (ICLR) in a cash and stock transaction valued at ~$12B.Per the terms of the agreement, PRA investors will receive $80 in cash and 0.4125 shares of ICON stock for each PR...
Icon (ICLR): Q4 GAAP EPS of $1.90 beats by $0.07.Revenue of $760.22M (+4.8% Y/Y) beats by $10.06M.Press Release For further details see: Icon EPS beats by $0.07, beats on revenue
Highlights Record net business wins in the quarter of $1,080 million; a book to bill of 1.42. Full year net business wins of $3.8 billion; a net book to bill of 1.38. Record closing backlog of $9.7 billion, an increase of 13.4% year on year. Quarter 4 reported ...
The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders. All cust...
ICON Public Limited (ICLR) has entered into an agreement with the privately held clinical-stage biotech company, Cytocom to manage the company’s Phase 3 clinical trial for its lead drug candidate, CYTO-201 in Crohn's disease."CYTO-201 is the program's lead clinical asset and we are ple...
Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-19 PR Newswire FORT COLLINS, Colo. , Feb. 16, 2021 /PRNewswire/ -- Cytocom, Inc. , a leading biopharmaceutical company creating first second...
News, Short Squeeze, Breakout and More Instantly...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...